Compare · TFX vs WST
TFX vs WST
Side-by-side comparison of Teleflex Incorporated (TFX) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TFX and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $25.31B, about 4.2x TFX ($5.96B).
- WST has been more active in the news (5 items in the past 4 weeks vs 3 for TFX).
- TFX has more recent analyst coverage (25 ratings vs 18 for WST).
- Company
- Teleflex Incorporated
- West Pharmaceutical Services Inc.
- Price
- $134.78-0.34%
- $358.18-1.11%
- Market cap
- $5.96B
- $25.31B
- 1M return
- -
- +8.72%
- 1Y return
- -
- +69.72%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 25
- 18
Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest TFX
- BMO Capital Markets initiated coverage on Teleflex with a new price target
- SEC Form 11-K filed by Teleflex Incorporated
- Teleflex Initiates Enrollment in Global BIOMAG™‑III Pivotal Trial of Freesolve™ Resorbable Magnesium Scaffold
- Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
- Director Randle Stuart A covered exercise/tax liability with 4,054 shares and was granted 5,658 shares, increasing direct ownership by 8% to 21,187 units (SEC Form 4)
- President and CEO Weidman Jason R. was granted 53,983 shares (SEC Form 4)
- SEC Form 3 filed by new insider Weidman Jason R.
- Teleflex Incorporated filed SEC Form 8-K: Leadership Update
- Four‑Year BIOMAG™-I Study Results Presented at EuroPCR Confirm Long‑Term Safety and Sustained Performance of the Freesolve™ Resorbable Magnesium Scaffold (DREAMS 3G)
- Teleflex upgraded by Piper Sandler with a new price target
Latest WST
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- BNP Paribas Exane initiated coverage on West Pharm with a new price target
- West to Host Second-Quarter 2026 Conference Call
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits